Donatienne Taylor
0000-0002-5141-513X
1 paper found
Refreshing results…
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
Missing publications? Search for publications with a matching author name.